Inogen, Inc (NASDAQ:INGN) EVP Byron Myers sold 10,000 shares of the stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $116.81, for a total transaction of $1,168,100.00. Following the completion of the sale, the executive vice president now directly owns 48,600 shares of the company’s stock, valued at $5,676,966. The transaction was disclosed in a filing with the SEC, which is available at this link.

Byron Myers also recently made the following trade(s):

  • On Friday, November 17th, Byron Myers sold 35,000 shares of Inogen stock. The stock was sold at an average price of $116.77, for a total transaction of $4,086,950.00.

Shares of Inogen, Inc (INGN) traded up $1.36 on Tuesday, reaching $118.65. 79,949 shares of the company’s stock were exchanged, compared to its average volume of 170,989. Inogen, Inc has a twelve month low of $62.69 and a twelve month high of $130.05. The stock has a market cap of $2,467.08, a price-to-earnings ratio of 96.11, a P/E/G ratio of 4.97 and a beta of 1.13.

Inogen (NASDAQ:INGN) last announced its quarterly earnings data on Tuesday, November 7th. The medical technology company reported $0.33 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.29 by $0.04. Inogen had a net margin of 11.36% and a return on equity of 13.37%. The business had revenue of $69.00 million during the quarter, compared to analyst estimates of $63.55 million. During the same period last year, the firm posted $0.25 EPS. The company’s revenue was up 26.8% on a year-over-year basis. sell-side analysts expect that Inogen, Inc will post 1.19 earnings per share for the current fiscal year.

INGN has been the subject of several analyst reports. Zacks Investment Research raised shares of Inogen from a “hold” rating to a “buy” rating and set a $131.00 target price for the company in a report on Thursday, November 9th. Needham & Company LLC increased their target price on shares of Inogen from $108.00 to $125.00 and gave the stock a “strong-buy” rating in a report on Wednesday, November 8th. Piper Jaffray Companies reissued a “hold” rating and issued a $90.00 target price on shares of Inogen in a report on Tuesday, September 12th. Leerink Swann reissued an “outperform” rating and issued a $120.00 target price (up from $115.00) on shares of Inogen in a report on Wednesday, November 8th. Finally, BidaskClub lowered shares of Inogen from a “buy” rating to a “hold” rating in a report on Tuesday, December 5th. Four analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Inogen currently has an average rating of “Buy” and an average target price of $103.14.

Institutional investors and hedge funds have recently made changes to their positions in the business. Schroder Investment Management Group purchased a new stake in Inogen during the 2nd quarter valued at approximately $132,000. Ameritas Investment Partners Inc. grew its holdings in Inogen by 6.1% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 1,495 shares of the medical technology company’s stock valued at $143,000 after buying an additional 86 shares in the last quarter. Sei Investments Co. grew its holdings in Inogen by 38.1% during the 2nd quarter. Sei Investments Co. now owns 1,606 shares of the medical technology company’s stock valued at $153,000 after buying an additional 443 shares in the last quarter. Victory Capital Management Inc. grew its holdings in Inogen by 17.8% during the 2nd quarter. Victory Capital Management Inc. now owns 2,036 shares of the medical technology company’s stock valued at $194,000 after buying an additional 307 shares in the last quarter. Finally, Pinebridge Investments L.P. grew its holdings in Inogen by 1.6% during the 2nd quarter. Pinebridge Investments L.P. now owns 2,143 shares of the medical technology company’s stock valued at $204,000 after buying an additional 33 shares in the last quarter.

WARNING: “Byron Myers Sells 10,000 Shares of Inogen, Inc (INGN) Stock” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/12/12/byron-myers-sells-10000-shares-of-inogen-inc-ingn-stock.html.

Inogen Company Profile

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Insider Buying and Selling by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.